CB2202 is a reversible inhibitor of monoamine oxidase-A (MAO-A) in the human brain to modulate key neurotransmitters which regulate different aspects of mood, cognition, and behaviour in human beings. Unlike older inhibitors of MAO-A, our candidate is devoid of potential tyramine induced side effects and provides enhanced tolerability. In addition, current medical opinion is in favour of selective, reversible MAO-A inhibitors as safe treatment in depression1,2. Through direct MAO-A inhibition the drug candidate addresses elevated MAO-A levels in elderly patients, where the larger portion of depression patients are found. By early 2017, CB2202 will be commencing phase II clinical trials in Major Depressive Disorder (MDD) patients.

  1. Goldberg JF and Thase ME, Monoamine oxidase inhibitors revisited: What you should know. J Clin Psychiatry 74: 189-191 (2013)
  2. Schulman KI et al., Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27: 789-797 (2013)